Skip to main content
perspectives
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
We are passionate about using our voices to advance our mission of developing life-transforming therapies for people living with serious muscle diseases.
Sep 15, 2022
Lessons Learned on Preparing to Weather the Inevitable Challenges in Biotech
by Joshua Brumm,
President & CEO of Dyne
Read more
Oct 7, 2021 |

From the Trenches: A LifeSci VC blog

by Josh Brumm

Read more
Sep 15, 2021 | Blog

Starting a New Tradition of Support

by Molly White, Dyne’s vice president, global head of patient advocacy and engagement

Read more
Jul 8, 2021 |

Playing To Win: Building A Position Of Strength In Biotech

by Josh Brumm

Read more
April 28, 2021 | BLOG

Toward a brighter future: targeting the genetic basis of rare muscle diseases

By Romesh Subramanian, Ph.D.

Read more
April 8, 2021 | BLOG

Scaling culture with growth: how to maintain your startup’s “special sauce”

By Joshua Brumm

Read more
Jan 8, 2021 | Life Science Leader panel

Preparing to pitch in a virtual world

Featuring Joshua Brumm

Watch
Dec 16, 2020 | BLOG

Beyond the balance sheet: thinking broadly about dilution in building a transformative biotech

By Joshua Brumm

Read more
Dec 14, 2020 | BLOG

Voice of the patient – the biopharma perspective

By Molly White

Read more
Oct 21, 2020 | PODCAST

FSHD Society Radio

By Molly White

Listen
Additional content
Stay connected with us on
Twitter, LinkedIn, and Facebook

Hear more from Dyne Therapeutics

On March 30, our Head of Platform Development, Timothy Weeden, will be presenting @Biologicsconf on the potential of our Force™ platform for targeted delivery of oligonucleotide therapeutics in muscle diseases. Register here: http://bit.ly/40skpAw #BiologicsSeries23

Hear more from our CEO, Joshua Brumm

These milestones represent the significant and urgent need for new treatments for people with #DMD. We look forward to working with the community and regulators to deliver a potentially transformative therapy for this devastating disease.